Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-5937 in Refractory Chronic Cough (CALM-1)
NCT05599191Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of camlipixant in refractory chronic cough (RCC) and unexplained chronic cough (3 arms), sponsored by GSK. Primary endpoints: 24-Hour Cough Frequency at 12 weeks and Number of Participants with Adverse Events and Serious Adverse Events at 52 weeks. Started Oct 2022; status: completed.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)unexplained chronic cough
Beyond the preview
Go deeper on NCT05599191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599191.